Domestic price of osimertinib

Osimertinib, brand name Tagrisso, is a third-generation EGFR tyrosine kinase inhibitor specifically used to treat patients with Patients with EGFRmutated non-small cell lung cancer (NSCLC), especially those who are resistant to first- and second-generation EGFR inhibitors. The main mechanism of action of osimertinib is to effectively inhibit the growth and spread of tumor cells by selectively inhibiting the mutant form of EGFR, especially the T790M drug-resistant mutation.

Osimertinib's highly effective inhibition of T790M mutations makes it a first- and second-line treatment for advanced non-small cell lung cancer (especially for patients with EGFR mutation-positive patients). Compared with other EGFR inhibitors, osimertinib has better targeting and fewer side effects. Common adverse reactions include rash, diarrhea, fatigue, etc., most of which are mild to moderate reactions.

In China, osimertinib was approved for marketing in2018 and has been included in China's medical insurance directory. It is mainly used to treat patients with EGFR mutation-positive, advanced or metastatic non-small cell lung cancer, especially those who have developed resistance to other EGFR inhibitors. The standard dose of osimertinib is 80mg, which is taken orally once a day. The medication is convenient and does not rely on food.

The domestic retail price of osimertinib is approximately 3000 yuan (per box 28 tablets), that is, the price of each tablet is about 100 yuan. The specific price may vary by region and pharmacy. Since osimertinib has been included in medical insurance, eligible patients can be reimbursed through medical insurance. The specific reimbursement ratio and scope need to be consulted with local hospitals and medical insurance institutions. For non-medical insurance patients, they can be purchased through private channels, but please note that the price is higher.

In summary, osimertinib, as a highly effective drug for the treatment of EGFR mutation-positive non-small cell lung cancer, has been launched in China and included in medical insurance, becoming an important treatment option for this type of patients.